Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 4/20 | 0.57 |
| ▸ | MMP2 | P08253 | 3/20 | 0.57 |
| ▸ | HTR2B | P41595 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 11/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 11/20 | 0.55 |
| ▸ | RECQL | P46063 | 7/20 | 0.55 |
| ▸ | MAPT | P10636 | 6/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.55 |
| ▸ | USP2 | O75604 | 5/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.55 |
| ▸ | TP53 | P04637 | 2/20 | 0.55 |
| ▸ | HBB | P68871 | 1/20 | 0.55 |
| ▸ | THRB | P10828 | 9/20 | 0.50 |
| ▸ | BLM | P54132 | 9/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | CASP1 | P29466 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | FNTA | P49354 | 1/20 | 0.44 |
| ▸ | FNTB | P49356 | 1/20 | 0.44 |
| ▸ | S100A4 | P26447 | 5/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30504362 | 0.94 | PTGS1 (0.56) | PTGS1MMP2HTR2BMEN1KMT2A | |
| Rodorubicin SCHEMBL8693 | 0.92 | MEN1 (0.58) | PTGS1MMP2HTR2BMEN1KMT2A | |
| Rodorubicin SCHEMBL29352818 | 0.92 | MEN1 (0.58) | PTGS1MMP2HTR2BMEN1KMT2A | |
| SCHEMBL29403905 | 0.92 | PTGS1 (0.54) | PTGS1MMP2HTR2BMEN1KMT2A | |
| SCHEMBL29884381 | 0.89 | PTGS1 (0.67) | PTGS1MMP2HTR2BMEN1KMT2A | |
| SCHEMBL29557045 | 0.89 | MMP2 (0.58) | PTGS1MMP2HTR2BMEN1KMT2A | |
| Aclacinomycin B SCHEMBL2500101 | 0.87 | MMP2 (0.74) | PTGS1MMP2HTR2BMEN1KMT2A | |
| Aclacinomycin B SCHEMBL29561911 | 0.87 | MMP2 (0.74) | PTGS1MMP2HTR2BMEN1KMT2A | |
| SCHEMBL29381144 | 0.85 | PTGS1 (0.50) | PTGS1MMP2HTR2BMEN1KMT2A | |
| SCHEMBL29467023 | 0.84 | PTGS1 (0.77) | PTGS1MMP2HTR2BMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1294 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116861-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-04-30 | — | — | US | claimed |
| US-12522572-B2 | Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-01-13 | — | — | US | claimed |
| US-20240343697-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2024-10-17 | — | — | US | claimed |
| US-11345956-B2 | Methods and compositions related to prostate cancer therapeutics | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-05-31 | — | — | US | claimed |
| US-20260146082-A1 | BISPECIFIC ANTI-MYOSTATIN AND ACTIVIN A ANTIBODY OR ANTIGEN BINDING FRAGMENTS THEREOF | IBIO, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| EP-4748449-A2 | USE OF SHORT CHAIN FATTY ACIDS IN CANCER PREVENTION | Temple University Of The Commonwealth System Of Higher Education (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-3704090-B1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-4748838-A1 | BROAD SPECTRUM ANTI-CANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-05-27 | — | — | EP | disclosed |
| US-12637510-B2 | Oncolytic virus compositions and methods for the treatment of cancer | CITY OF HOPE (US) | 2026-05-26 | — | — | US | disclosed |
| US-20260137630-A1 | COMPOSITIONS AND METHODS FOR T CELL TARGETED DELIVERY OF THERAPEUTIC AGENTS AND ACTIVATION OF T CELLS | THE TRUSTEES OF THE UNIV OF PENNSYLVANIA (US) | 2026-05-21 | — | — | US | disclosed |
| US-12630527-B2 | Broad spectrum anti-cancer compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-05-19 | — | — | US | disclosed |
| WO-2026102111-A1 | METHODS FOR TREATING OR PREVENTING PROSTATE CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-05-15 | — | — | WO | disclosed |
| US-11241423-B2 | Antiproliferative compounds and methods of use thereof | CELGENE CORPORATION (US) | 2022-02-08 | — | — | US | disclosed |
| US-11241500-B2 | HSP90-targeting conjugates and formulations thereof | TARVEDA THERAPEUTICS, INC. (US) | 2022-02-08 | — | — | US | disclosed |
| US-11241455-B2 | Methods of treating disease by metabolic control of T-cell differentiation | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2022-02-08 | — | — | US | disclosed |
| WO-2022023772-A1 | ANTAGONIST COMPOUNDS | AdoRx Therapeutics Limited (GB) | 2022-02-03 | — | — | WO | disclosed |
| US-20220031641-A1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING COGNITIVE DYSFUNCTION | PHARMATROPHIX, INC. | 2022-02-03 | — | — | US | disclosed |
| US-20220031853-A1 | HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF | TVA (ABC), LLC | 2022-02-03 | — | — | US | disclosed |
| EP-3941905-A1 | SUMO INHIBITOR COMPOUNDS AND USES THEREOF | Suvalent Therapeutics, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
| EP-3941919-A1 | PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AS INHIBITORS OF ENDORIBONUCLEASE INOSITOL REQUIRING ENZYME I (IRE I ALPHA) FOR THE TREATMENT OF CANCER DISEASES | Genentech, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260116861-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | HDAC3, HDAC1, HDAC4 | PTGS1 4049/4885MMP2 490/4885HTR2B 1731/4885 |
| US-20260137630-A1 | COMPOSITIONS AND METHODS FOR T CELL TARGETED DELIVERY OF THERAPEUTIC AGENTS AND ACTIVATION OF T CELLS | LCP2, CD47, CD4 | PTGS1 3298/4885MMP2 3675/4885HTR2B 4534/4885 |
| US-12637510-B2 | Oncolytic virus compositions and methods for the treatment of cancer | CD47, IGLV6-57, STING1 | PTGS1 4034/4885MMP2 3828/4885HTR2B 3935/4885 |
| US-20220031641-A1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING COGNITIVE DYSFUNCTION | CHRM3, CHAT, CHRM5 | PTGS1 671/4885MMP2 2013/4885HTR2B 89/4885 |
| US-11241423-B2 | Antiproliferative compounds and methods of use thereof | MCL1, MKI67, BAX | PTGS1 704/4885MMP2 894/4885HTR2B 4194/4885 |
| US-12630527-B2 | Broad spectrum anti-cancer compounds | YTHDF3, YTHDF1, YTHDF2 | PTGS1 4874/4885MMP2 3686/4885HTR2B 2754/4885 |
| US-11241500-B2 | HSP90-targeting conjugates and formulations thereof | HSP90AB1, HSP90AA1, HSP90B1 | PTGS1 2126/4885MMP2 740/4885HTR2B 4307/4885 |
| US-20220031853-A1 | HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF | HSP90AB1, HSP90AA1, HSP90B1 | PTGS1 2126/4885MMP2 740/4885HTR2B 4307/4885 |
| US-20260146082-A1 | BISPECIFIC ANTI-MYOSTATIN AND ACTIVIN A ANTIBODY OR ANTIGEN BINDING FRAGMENTS THEREOF | MSTN, MST1R, MYOF | PTGS1 4780/4885MMP2 3212/4885HTR2B 3233/4885 |
| US-20240343697-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | HDAC1, HDAC7, HDAC5 | PTGS1 2311/4885MMP2 177/4885HTR2B 2266/4885 |
| US-11241455-B2 | Methods of treating disease by metabolic control of T-cell differentiation | GOT1, IL17A, OGDH | PTGS1 223/4885MMP2 4298/4885HTR2B 4652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.